Schlachtenberger, Georg ORCID: 0000-0001-7118-8432, Doerr, Fabian, Menghesha, Hruy, Lauinger, Patrick ORCID: 0000-0002-9338-639X, Wolber, Philipp, Sabashnikov, Anton, Popov, Aron-Frederik, Macherey-Meyer, Sascha, Bennink, Gerardus, Klussmann, Jens P., Wahlers, Thorsten, Hekmat, Khosro and Heldwein, Mathias B. (2022). Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review. Med. Lith., 58 (8). BASEL: MDPI. ISSN 1648-9144

Full text not available from this repository.

Abstract

Background and Objectives: The incidence of distant metastases in patients with head and neck cancer (HNC) is approximately 10%. Pulmonary metastases are the most frequent distant location, with an incidence of 70-85%. The standard treatment options are chemo-, immuno- and radiotherapy. Despite a benefit for long-term survival for patients with isolated pulmonary metastases, pulmonary metastasectomy (PM) is not the treatment of choice. Furthermore, many otorhinolaryngologists are not sufficiently familiar with the concept of PM. This work reviews the recent studies of pulmonary metastatic HNC and the results after pulmonary metastasectomy. Materials and Methods: PubMed, Medline, Embase, and the Cochrane library were checked for the case series' of patients undergoing metastasectomy with pulmonary metastases published since 1 January 2000. Results: We included the data of 15 studies of patients undergoing PM. The 5-year survival rates varied from 21% to 59%, with median survival from 10 to 77 months after PM. We could not identify one specific prognostic factor for long-term survival after surgery. However, at least most studies stated that PM should be planned if a complete (R0) resection is possible. Conclusions: PM showed reliable results and is supposedly the treatment of choice for patients with isolated pulmonary metastases. Patients not suitable for surgery may benefit from other non-surgical therapy. Every HNC patient with pulmonary metastases should be discussed in the multidisciplinary tumor board to optimize the therapy and the outcome.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Schlachtenberger, GeorgUNSPECIFIEDorcid.org/0000-0001-7118-8432UNSPECIFIED
Doerr, FabianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Menghesha, HruyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lauinger, PatrickUNSPECIFIEDorcid.org/0000-0002-9338-639XUNSPECIFIED
Wolber, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sabashnikov, AntonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Popov, Aron-FrederikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Macherey-Meyer, SaschaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bennink, GerardusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klussmann, Jens P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wahlers, ThorstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hekmat, KhosroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heldwein, Mathias B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-674769
DOI: 10.3390/medicina58081000
Journal or Publication Title: Med. Lith.
Volume: 58
Number: 8
Date: 2022
Publisher: MDPI
Place of Publication: BASEL
ISSN: 1648-9144
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SQUAMOUS-CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; LUNG METASTASECTOMY; DISTANT METASTASES; SURGICAL RESECTION; 1ST-LINE TREATMENT; THYROID-CARCINOMA; ORAL-CAVITY; OPEN-LABEL; RECURRENTMultiple languages
Medicine, General & InternalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/67476

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item